CCL25 and cranioectodermal dysplasia: While a previous preclinical study in a mouse model of Crohn’s disease (TNF∆ARE) had shown that CCX282-B was capable of inhibiting the CCL25-induced chemotaxis mediated by CCR9A and B, and thus exert a preventive effect on intestinal inflammation [93], results in the context of CeD have not been published yet.